**Core tip:** Non-invasive evaluation of hepatic fibrosis is important in infants with cholestasis including biliary atresia. Periportal thickening (PT) and normalized spleen size ratio (SR) measured on liver magnetic resonance imaging (MRI) showed positive correlations with hepatic fibrosis grade, even after adjusting age. For the diagnosis of significant fibrosis (F2-F4), PT using the cutoff of 4.2 mm showed higher diagnostic performance than SR or aspartate transaminase to platelet ratio index. For the diagnosis of cirrhosis (F4), SR was the best. Therefore, liver MRI findings of PT and SR can be useful to assess clinically significant hepatic fibrosis (F2 and higher) in infants with cholestasis.

INTRODUCTION
============

Neonatal cholestasis, an intrahepatic or extrahepatic disorder, is defined as persistent conjugated hyperbilirubinemia more than 2 wk and may be caused by various diseases\[[@B1]\]. Untreated neonatal cholestasis can progress to liver cirrhosis or end stage liver disease in infants due to prolonged hepatocyte and biliary tree injury and may require liver transplantation. Ultimately, the degree of hepatic fibrosis in infantile cholestasis is a major determinant of the patient\'s outcome\[[@B2]\]. For biliary atresia (BA), a previous study reported that severe hepatic fibrosis at the time of Kasai operation, irrespective of age, carried a poor outcome and the degree of hepatic fibrosis, as well as the time of operation, is an important factor for survival after Kasai operation\[[@B3],[@B4]\]. Therefore, knowing the degree of hepatic fibrosis before the operation can help predict the treatment methods and outcomes of patients and prepare for subsequent liver transplants.

Hepatic fibrosis in neonates and infants can be measured by serology, ultrasound elastography, and liver biopsy\[[@B5]\]. Ultrasound elastography is non-invasive, but has the disadvantage that the accuracy of the test may be impaired if the practitioner lacks experience or if ascites exists in the perihepatic space. Liver biopsy is necessary for confirmation of biliary disease including BA as an accurate diagnostic tool and assessment of hepatic fibrosis, but it is an invasive method and has the disadvantage that it cannot be repeatedly performed due to complications of the test itself\[[@B6],[@B7]\].

Magnetic resonance imaging (MRI) has been reported to be useful for differential diagnosis of cholestatic jaundice in infants with high resolution and quantitative evaluation\[[@B8]\]. Several previous studies investigating diagnosis of BA by MRI evaluated visibility of the extrahepatic bile duct on MR cholangiopancreatography (MRCP)\[[@B9]-[@B11]\], but it has been reported that the accuracy of BA diagnosis was improved when the triangular cord thickness or periportal thickening (PT), which is usually measured on ultrasonography, was applied to MRI\[[@B12]\]. We thought if these MRI findings were associated with hepatic fibrosis, degree of hepatic fibrosis could be predicted noninvasively and reproducibly by making less susceptible to practitioner's skill than ultrasonography. However, there was no previous study showing that MRI findings including PT reflect the degree of hepatic fibrosis in patients with infantile cholestasis. Therefore, we investigated whether the PT and spleen size measured on MRI is associated with pathologically assessed hepatic fibrosis in patients with infantile cholestasis.

MATERIALS AND METHODS
=====================

This retrospective study was approved by our Institutional Review Board, with a waiver for informed consent for reviewing medical records and images of the patients. However, written informed consent for sedation and MRI was received before each examination as routine clinical practice.

Patients and basic characteristics
----------------------------------

We included all consecutive patients between July 2009 and October 2017 who (1) underwent both liver MRI and liver biopsy to evaluate the cause of infantile cholestasis which was defined as prolonged hyperbilirubinemia longer than 2 wk; (2) were younger than 6 mo at the time of MRI as identified by chart review; and (3) had an interval between liver MRI and liver biopsy within 1 mo. We do liver MRI and liver biopsy in infants with persistent jaundice after conservative treatment. We also do liver biopsy during BA and choledochal cyst operation in neonates and infants as a routine protocol. Patient's sex and age at the time of MRI, laboratory results at the time of MRI and etiology of cholestasis confirmed by pathology and/or operative cholangiography (BA *vs* non-BA) were evaluated through medical chart review.

MRI acquisition and interpretation
----------------------------------

All MR images were obtained using a 1.5-T unit (Intera Achieva; Philips Healthcare) with a cardiac coil and patients were sedated by general anesthesia under the supervision of anesthesiologists. MR sequences used at our hospital included respiratory gated T2-weighted fast spine echo (FSE) axial, T1-weighted spin echo axial, T2-weighted single shot FSE sagittal, and respiratory gated FSE 3 dimensional MRCP coronal images. Repetition time/echo time was 2000/100 ms for FSE T2, 600/11 for T1, 700/80 for single shot FSE T2, and 1500/650 for MRCP. Matrix was 256 × 256. Section thickness was 2 mm with 1 mm gap for MRCP and 3 mm without gap for the others. Field of view was 18-24 cm. The total scan time for our protocol was approximately 15 -20 min for most of the cases.

Two radiologists (with 15 and 4 years of clinical experience in pediatric radiology, respectively) who were unaware of the final diagnosis analyzed the MR images in consensus on the picture archiving and communication system (Centricity; GE Healthcare). The PT measured on MRI was defined as the maximal thickness of periportal signal change on MRI which was measured (1) either along the right main or left main portal vein; and (2) on either side of the portal vein where its thickness was the greatest. The maximum thickness of the periportal signal change was separately measured on T1-weighted axial, T2-weighted axial and T2-weighted sagittal images, and then the largest value among the three measurements was selected (Figure [1](#F1){ref-type="fig"})\[[@B12]\]. The size of the spleen was defined as the maximum length of spleen either measured on T2-weighted axial or sagittal images, and the larger value was used for analysis. Then we analyzed the normalized spleen size ratio (SR)\[[@B13]\] by calculating the maximum spleen length divided by the upper normal limit of size according to the patient's age and sex\[[@B14]\].

![Example of measuring of periportal thickening on magnetic resonance imaging. Pancreaticobiliary magnetic resonance imaging of a 3-mo-old girl diagnosed as biliary atresia. A: On T1-weighted axial image, the maximal thickness of periportal signal change was measured on right main portal vein where its greatest thickness was 5.5 mm; B: On T2-weighted sagittal image, the maximal thickness of periportal signal change was 6.1 mm. Therefore, the larger of the two, which was measured on T2-weighted sagittal image, was defined as periportal thickening of this patient.](WJG-26-2821-g001){#F1}

Liver biopsy and histologic grade
---------------------------------

Basically, ultrasonography-guided liver biopsy was performed using an 18-gauge core biopsy needle (TSK Stericut Standard type with Co-axial; TSK) with a free-hand technique under sedation supervised by anesthesiologists in patient with infantile cholestasis. However, if BA or choledochal cyst was strongly suspected, liver biopsy was performed during operation.

All specimens were evaluated for histopathologic diagnosis of cholestasis and grading hepatic fibrosis by hepatobiliary pathologists. The fibrosis grades of pathologic specimens of all cases were evaluated by METAVIR fibrosis grade, ranging from grade F0 to F4 (F0, no fibrosis; F1, portal fibrosis without septa; F2, portal fibrosis with few septa; F3, numerous septa without cirrhosis; and F4, cirrhosis). Clinically significant fibrosis was defined as grade F2 to F4 and advanced fibrosis was defined as grade F3 to F4\[[@B15],[@B16]\].

 

Serologic evaluation
--------------------

Laboratory results included aspartate aminotransferase (AST), alanine transaminase and platelet count. We calculated the AST-to-platelet ratio index (APRI), known as a noninvasive fibrosis score by serology, which is calculated as \[(AST/upper limit of normal AST) × 100\]/platelet count (10^9^/L).

Statistical analysis
--------------------

Statistical analyses were performed using SPSS version 23 (IBM Corp.). The independent two-sample *t* test for continuous variables and *χ*^2^ test for categorical variables were used. Analysis of variance was used for the comparison of parameters with different hepatic fibrosis grades. Correlation between laboratory or imaging parameters and hepatic fibrosis grades was analyzed using Kendall's tau correlation coefficient. The diagnostic performances of parameters for clinically significant or advanced fibrosis and cirrhosis were evaluated by a receiver operating characteristic (ROC) curve analysis. The optimal cut-off values from the ROC curves were determined by the Youden index. The area under the ROC curve (AUC) of the parameters was compared with a *Z* test. In all tests, a *P* value less than 0.05 was considered statistically significant.

RESULTS
=======

Subjects
--------

During the study period, 155 patients with infantile cholestasis were included. Baseline characteristics of our study are summarized in Table [1](#T1){ref-type="table"}. The mean age at the time of MRI was 57.6 ± 34.4 d and 94 patients (60.6%) were female. Among the patients, 110 infants (71%) were diagnosed with BA and the remaining 45 (29%) were diagnosed with diseases other than BA by pathologic confirmation. The final diagnoses of the non-BA patients were choledochal cyst (*n* = 29), hepatitis (*n* = 8), paucity of intrahepatic bile ducts (*n* = 3), and other metabolic diseases (*n* = 5).

###### 

Clinical summary of the patients with infantile cholestasis

                                      **Overall (*n* = 155)**   **BA (*n* = 110)**   **Non-BA (*n* = 45)**   ***P* value**
  ----------------------------------- ------------------------- -------------------- ----------------------- ---------------
  Demographics                                                                                               
  Age (d)                             57.6 ± 34.4               59.7 ± 30.3          52.4 ± 42.8             0.303
  Gender (M:F)                        61:94                     41:69                20:25                   0.470
  Laboratory results                                                                                         
  APRI                                1.32 ± 1.61               1.47 ± 1.66          0.95 ± 1.42             0.069
  Imaging findings                                                                                           
  PT (mm)                             4.9 ± 1.8                 5.7 ± 1.4            2.9 ± 0.9               \< 0.001
  SR                                  1.02 ± 0.20               1.07 ± 0.19          0.91 ± 0.17             \< 0.001
  METAVIR grades (Patients' number)                                                                          
  F0/F1/F2/F3/F4                      32/10/66/37/10            1/4/59/37/9          31/6/7/0/1              \< 0.001

*P* values from independent *t*-test except for gender and fibrosis grades from *χ*^2^ test. BA: Biliary atresia; APRI: Aspartate transaminase to platelet ratio index; SR: Normalized spleen size ratio; PT: Periportal thickening.

The mean age at the time of MRI was not different between the BA and non-BA groups (*P* = 0.303). The PT and SR were significantly higher in the BA group than in the non-BA group (*P* \< 0.001), but ARPI was not different (Table [1](#T1){ref-type="table"}). The number of patients with clinically significant fibrosis (F2--F4) was 113 (72.9%), with 105 from the BA group and 8 from the non-BA group. There were 47 patients (30.3%) with advanced fibrosis (F3--F4), with 46 from the BA group and 1 from the non-BA group. The distribution of each hepatic fibrosis grade is detailed in Table [1](#T1){ref-type="table"}. There were 9 BA and 1 non-BA patients with liver cirrhosis (F4).

Comparison and correlation between parameters and hepatic fibrosis grades
-------------------------------------------------------------------------

Table [2](#T2){ref-type="table"} summarizes the results of parameters in each fibrosis grading group. Age, APRI, PT, and SR were different in the fibrosis group comparison. Correlation analysis also demonstrated positive correlation between these parameters and fibrosis grades (all, *P* \< 0.001). However, after adjusting age, partial correlation results demonstrated that only PT (τ = 0.518, *P* \< 0.001) and SR (τ = 0.340, *P* \< 0.001) showed positive correlations with the hepatic fibrosis grades. Representative images of each hepatic fibrosis grade are shown in Figure [2](#F2){ref-type="fig"}.

###### 

Comparison and correlation analyses for fibrosis grading

                                           **Age (d)**   **APRI**      **PT (mm)**   **SR**
  ---------------------------------------- ------------- ------------- ------------- -------------
  Hepatic fibrosis group comparison                                                  
  F0 (*n* = 32)                            40.8 ± 34.8   1.12 ± 1.63   3.1 ± 1.1     0.89 ± 0.15
  F1 (*n* = 10)                            60.6 ± 44.0   0.46 ± 0.38   3.3 ± 1.3     0.94 ± 0.20
  F2 (*n* = 66)                            52.3 ± 31.0   1.14 ± 1.23   5.2 ± 1.4     1.01 ± 0.17
  F3 (*n* = 37)                            71.9 ± 28.6   2.00 ± 2.27   5.9 ± 1.6     1.12 ± 0.20
  F4 (*n* = 10)                            89.7 ± 26.6   1.52 ± 0.55   5.7 ± 1.6     1.21 ± 0.17
  *P* value                                \< 0.001      0.026         \< 0.001      \< 0.001
  Correlation analysis                                                               
  Overall correlation                                                                
  τ                                        0.313         0.326         0.448         0.361
  *P* value                                \< 0.001      \< 0.001      \< 0.001      \< 0.001
  Partial correlation with adjusting age                                             
  τ                                                      0.071         0.518         0.340
  *P* value                                              0.405         \< 0.001      \< 0.001

*P* values from analysis of variance for group comparisons and Kendall's tau for correlation analyses. APRI: Aspartate transaminase to platelet ratio index; PT: Periportal thickening, SR: Normalized spleen size ratio.

![Representative images of periportal thickening for each hepatic fibrosis grade. The maximal thickness (double arrow in each figure) of periportal signal intensity change was measured. A: 2.7 mm on axial T2-weighted image in a 7-d-old girl with non-biliary atresia (non-biliary atresia, choledochal cyst) and hepatic fibrosis grade 1 (F1); B: 4.2 mm on T2-weighted axial image in a 2-mo-old girl with BA and F2; C: 5.5 mm on T1-weighted axial image in a 3-mo-old girl with biliary atresia and F3; D: 5.4 mm on T2-weighted axial image in a 2-mo-old girl with non-biliary atresia (metabolic disease) and F4.](WJG-26-2821-g002){#F2}

Assessment of diagnostic performance of parameters for clinically significant or advanced fibrosis and cirrhosis
----------------------------------------------------------------------------------------------------------------

The diagnostic performances in diagnosing clinically significant fibrosis (F0--F1 *vs* F2--F4), advanced fibrosis (F0--F2 *vs* F3--F4), and cirrhosis (F0-F3 *vs* F4) for each parameter are shown in Table [3](#T3){ref-type="table"}. The AUCs of PT were 0.899 (95%CI: 0.840--0.941) using a cutoff value of 4.2 mm for clinically significant fibrosis and 0.734 (95%CI: 0.657--0.801) with a cutoff of 5.3 mm for advanced fibrosis (*P* \< 0.001). The AUCs of SR and APRI were 0.741 with a cutoff value of 0.85 and 0.712 with a cutoff of 0.44 for the diagnosis of clinically significant fibrosis, respectively. For diagnosing advanced fibrosis, the AUC of SR was 0.742 with a cutoff value of 1.1 and that of APRI was 0.724 with a cutoff value of 0.78. For diagnosing cirrhosis, the AUC was the highest with SR as 0.790 (95%CI: 0.718-0.852) with a cutoff value of 1.04. However, the AUC of PT was not significant (*P* = 0.058).

###### 

Diagnostic performance of the parameters

  **Variable**                              **Cutoff value**   **Sensitivity (%)**   **Specificity (%)**   **AUC**   **95%CI**     ***P* value**
  ----------------------------------------- ------------------ --------------------- --------------------- --------- ------------- ---------------
  Clinically significant fibrosis (F2-F4)                                                                                          
  APRI                                      0.44               84.1                  59.5                  0.712     0.634-0.782   0.001
  PT                                        4.2 mm             81.4                  85.7                  0.899     0.840-0.941   \< 0.001
  SR                                        0.85               85.0                  54.8                  0.741     0.664-0.808   \< 0.001
  Advanced fibrosis (F3-F4)                                                                                                        
  APRI                                      0.78               78.7                  63.0                  0.724     0.647-0.793   \< 0.001
  PT                                        5.3 mm             66.0                  71.3                  0.734     0.657-0.801   \< 0.001
  SR                                        1.1                61.7                  78.7                  0.742     0.666-0.809   \< 0.001
  Cirrhosis (F4)                                                                                                                   
  APRI                                      1.24               90.0                  70.3                  0.715     0.637-0.785   0.002
  PT                                        5.3 mm             70.0                  62.1                  0.656     0.675-0.730   0.058
  SR                                        1.04               90.0                  61.4                  0.790     0.718-0.852   \< 0.001

AUC: Area under the curve; APRI: Aspartate transaminase to platelet ratio index; PT: Periportal thickening; SR: Normalized spleen size ratio.

Comparison of diagnostic performance of parameters for clinically significant or advanced fibrosis and cirrhosis
----------------------------------------------------------------------------------------------------------------

For diagnosing clinically significant fibrosis, there was a significant difference in the AUC between PT and SR (difference between area, 0.158; *P* \< 0.001) and PT and APRI (difference between area, 0.186; *P* \< 0.001), but no significant difference between SR and APRI (difference between area, 0.029; *P* = 0.613). The AUC of PT (0.899) was significantly higher than those of SR (0.741) and APRI (0.712) (Figure [3A](#F3){ref-type="fig"}).

![Comparisons of receiver operating characteristic curves. The comparisons of area under the curve (AUC) for diagnosing A: Clinically significant fibrosis (F2-F4); B: Advance fibrosis (F3-F4); C: Cirrhosis (F4) with periportal thickening (PT, green line), normalized spleen size ratio (SR, orange line), and aspartate aminotransferase to platelet ratio index (APRI, blue line). The AUC of PT for diagnosing clinically significant fibrosis was higher than that of SR or APRI. However, the AUCs were not different for differentiating advanced fibrosis. For diagnosing cirrhosis, SR had higher AUC value than PT. APRI: Aspartate aminotransferase to platelet ratio index; SR: Normalized spleen size ratio; PT: Periportal thickening.\
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 ](WJG-26-2821-g003){#F3}

In contrast, there were no significant differences in the AUCs between PT, SR and APRI for diagnosing advanced fibrosis. The differences between areas were 0.008 (*P* = 0.873) between PT and SR, 0.009 (*P* = 0.859) between PT and APRI, and 0.018 (*P* = 0.724) between SR and APRI (Figure [3B](#F3){ref-type="fig"}).

In cirrhosis, the AUC with SR was higher than that with PT (difference between area, 0.135; *P* = 0.041), but not that with APRI (difference between area, 0.075; *P* = 0.427). There was no significant difference in the AUCs between PT and APRI (difference of 0.060, *P* = 0.626) (Figure [3C](#F3){ref-type="fig"}).

DISCUSSION
==========

Serologic marker of APRI and splenomegaly are well known markers for the evaluation of hepatic fibrosis in adults, but there is limited study about these parameters in infants. Moreover, this is the first study suggested the usefulness of PT for investigating hepatic fibrosis in infants with cholestasis. We demonstrated that PT measured on MRI showed positive correlation with pathologically assessed hepatic fibrosis grades and had good performance to diagnose both clinically significant fibrosis and advanced fibrosis with cutoff values of 4.2 mm and 5.3 mm, respectively. In addition, hepatic fibrosis was also significantly correlated with SR and APRI, but the diagnostic performance of PT measured on MRI for clinically significant hepatic fibrosis was superior to that of SR and APRI. Moreover, after adjusting age, only PT and SR showed positive correlations with the hepatic fibrosis grades. Therefore, our study shows that MRI findings of PT and SR are useful in predicting the degree of hepatic fibrosis in infants with cholestasis who cannot easily undergo liver biopsy.

To determine grade of hepatic fibrosis in patients with neonatal cholestasis, liver biopsy is the gold standard. However, it is invasive and can result in severe, life-threatening complications in infants and neonates\[[@B17]-[@B19]\]. Moreover, this procedure is associated with significant sampling error\[[@B20]\]. Therefore, several methods for non-invasive assessment of hepatic fibrosis in infants and neonates have been proposed. APRI by laboratory test could be a reliable method to assess advanced fibrosis (F3--F4) and liver cirrhosis (F4) at the time of Kasai operation and postoperative follow-up care\[[@B21]\]. APRI has shown significant correlation with hepatic fibrosis grade in children with chronic liver disease\[[@B5]\]. These studies are consistent with our study, in which APRI of our patients showed significant correlation with hepatic fibrosis grade and good performance to diagnose clinically significant fibrosis and advanced fibrosis. However, APRI was not correlated with hepatic fibrosis grades after adjusting age.

Another tool is transient elastography, which could suggest optimal time of Kasai operation in patients with BA\[[@B22]\]. There have been several reports on the utility of this technique to evaluate hepatic fibrosis and cirrhosis in patients with BA\[[@B23]-[@B25]\]. However, there are limitations in the aforementioned studies in that they could not evaluate the diagnostic performance of clinically significant fibrosis (F2--F4) and operator dependency of this method\[[@B7],[@B23],[@B25],[@B26]\].

Triangular cord sign or PT was a concept originally designed for ultrasound, which is represented by triangular cone-shaped fibrous tissue in the bifurcation of the portal vein at the porta hepatis. However, due to operator dependence on ultrasound, the concept of PT measured on MRI has been proposed and defined as a thickening of periportal signal change on T1 or T2-weighted images\[[@B27],[@B28]\]. A recent study also proposed that an MRI-based decision tree for diagnosis of BA using PT on MRI with a cutoff value of 5.1 mm showed high sensitivity (97.3%) and specificity (94.8%)\[[@B12]\]. PT measured on ultrasonography was associated with hepatic fibrosis in BA, but there was no significant association between PT and hepatic fibrosis grade\[[@B23]\]. And there was a few previous study on whether PT measured on MRI is associated with hepatic fibrosis in patients with neonatal cholestasis with relatively small population\[[@B28]\]. Because this was a retrospective study and there were limited data about PT on ultrasonography in non-biliary atresia patients, we could not evaluate the diagnostic performance of PT on ultrasonography compared with that on MRI. However, as ultrasonography is a more available and easily accessible technique, further study is needed for this topic.

Degree of hepatic fibrosis at time of Kasai operation is known to be one of the prognostic factors after Kasai operation in patients with BA\[[@B3],[@B29]\]. Many previous studies have focused on age at time of surgery, but a few studies have suggested that severe fibrosis at the time of Kasai operation, irrespective of age, carries a poor outcome\[[@B3],[@B30]\]. Severe fibrosis was associated with unsuccessful outcome of Kasai operation without biliary drainage and all patients with cirrhosis had no biliary drainage after Kasai operation in a previous study\[[@B4]\]. Therefore, in patients with advanced fibrosis and liver cirrhosis at the time of diagnosis, early liver transplantation may improve prognosis over Kasai portoenterostomy\[[@B23],[@B31]\]. A few retrospective studies suggested that anti-inflammatory and immunomodulatory drugs such as steroids might alter progression of hepatic fibrosis and improve biliary drainage and survival rate of native liver of patients\[[@B32]\]. Considering that hepatic fibrosis progresses even after surgery, degree of hepatic fibrosis both before and after surgery could be associated with postoperative complications and prognosis in BA. A prospective study is needed on whether the imaging findings of PT are also relevant to the patient\'s prognosis.

There were several limitations in this study. First, this study was performed retrospectively, so inherent possibility of bias exists. Second, reproducibility of PT measurements could be problematic, even though we used consensus reading. Third, we could not evaluate the pathologic finding of PT. The meaning of PT as a direct or indirect finding of hepatic or periportal fibrosis should be evaluated. Finally, the number of patients with F1 and F4 was relatively small, leading to unreliable data from these groups.

In conclusion, liver MRI findings of PT and SR can be useful to assess hepatic fibrosis in infants with cholestasis including BA. The finding of PT with a cutoff value of 4.2 mm has better diagnostic performance to predict clinically significant fibrosis than either SR or APRI. And SR had the highest diagnostic performance value for differentiating cirrhosis. The degree of hepatic fibrosis is an important prognostic factor after Kasai operation in patients with BA. Therefore, PT and SR measured on MRI may help predict prognosis of BA and suggest more effective non-invasive treatment options.

ARTICLE HIGHLIGHTS
==================

Research background
-------------------

Untreated neonatal cholestasis can progress to liver cirrhosis or end stage liver disease in infants due to prolonged hepatocyte and biliary tree injury and may require liver transplantation. Therefore, non-invasive evaluation of hepatic fibrosis is important in infants with cholestasis including biliary atresia.

Research motivation
-------------------

Some serologic tests and splenomegaly are known markers for the evaluation of hepatic fibrosis in adults, but there is limited study about these parameters in infants. Periportal thickening (PT) was only considered as the finding of biliary atresia and has not been evaluated for assessing hepatic fibrosis in infants with cholestasis.

Research objectives
-------------------

We investigated whether the PT and spleen size measured on magnetic resonance imaging (MRI) is associated with pathologically assessed hepatic fibrosis in patients with infantile cholestasis including biliary atresia.

Research methods
----------------

This retrospective study included infants less than 6 mo with liver MRI and biopsy for the evaluation of infantile cholestasis. Not only PT and spleen size measured on MRI, but also serologic assessment of aspartate transaminase to platelet ratio index (APRI) were evaluated and compared with histopathologic METAVIR grading of hepatic fibrosis. We calculated normalized spleen size ratio (SR) using the upper normal size limit.

Research results
----------------

A total of 155 patients were evaluated including 110 with biliary atresia. Mean age at the time of MRI was 57.6 ± 34.4 d. There were positive correlations between fibrosis grade and PT and SR, even after adjusting age. The finding of PT with a cutoff value of 4.2 mm has better diagnostic performance to predict clinically significant fibrosis than either SR or APRI. And SR had the highest diagnostic performance value for differentiating cirrhosis.

Research conclusions
--------------------

Liver MRI findings of PT and SR are useful to assess clinically significant hepatic fibrosis (F2 and higher) in infants with cholestasis including biliary atresia.

Research perspectives
---------------------

The degree of hepatic fibrosis is an important prognostic factor after Kasai operation in patients with biliary atresia. Therefore, PT and SR measured on MRI may help predict prognosis of biliary atresia and suggest more effective non-invasive treatment options.
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